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Abstract
Background: In the elderly in Scandinavia, multi-dose drug dispensing (MDD) is a common alternative to ordinary
prescriptions (OP). MDD patients receive their drugs in unit bags, one for each dose occasion. The prescribing procedure
differs between MDD and OP. The aim of the present study was to investigate the association between MDD and quality of
drug treatment (QDT).
Methodology/Principal Findings: A cross-sectional study was performed of all inhabitants in Region Va ¨stra Go ¨taland alive
on December 31st 2007, aged $65 years, with $1 prescribed drug and $2 health care visits for $2 diagnoses for
obstructive pulmonary disease, diabetes mellitus, and/or cardiovascular disease in 2005–2007 (n=24,146). For each patient,
drug treatment on December 31st 2007 was estimated from drugs registered in the Swedish Prescribed Drug Register. QDT
was evaluated according to established quality indicators ($10 drugs, Long-acting benzodiazepines, Drugs with
anticholinergic action, $3 psychotropics, and Drugs combinations that should be avoided). Logistic regression, with
adjustments for age, sex, burden of disease, and residence, was performed to investigate the association between MDD and
QDT. Mean age was 77 years, 51% were females, and 20% used MDD. For all quality indicators, the proportion of patients
with poor QDT was greater in patients with MDD than in patients with OP (all P,0.0001). Unadjusted and adjusted odds
ratios (95% confidence intervals) for poor QDT (MDD patients vs. OP patients) ranged from 1.47 (1.30–1.65) to 7.08 (6.30–
7.96) and from 1.36 (1.18–1.57) to 5.48 (4.76–6.30), respectively.
Conclusions/Significance: Patients with MDD have poorer QDT than patients with OP. This cannot be explained by
differences in age, sex, burden of disease, or residence. These findings must be taken into account when designing
alternative prescribing systems. Further research is needed to evaluate causative factors and if the findings also apply to
other dose dispensing systems.
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Introduction
Dose dispensing systems are widespread over the world, but
limited knowledge is available on safety aspects of such systems [1].
An important safety concern is quality of prescribing. Indeed, the
prescriber rather than the nursing and pharmacy services accounts
for the majority of medication errors, as well as for the majority of
severe medication errors [2]. Quality of prescribing can be
measured by drug-specific quality indicators. These are quantita-
tive measures based on international literature on quality of drug
use. In Sweden, the National Board of Health and Welfare has
developed quality indicators to measure quality of drug treatment
in older people [3]. These have been used both in research [4,5]
and for benchmarking [6].
In Sweden, about 182,000 out of 9 million inhabitants use the
multi-dose drug dispensing (MDD) system ApoDosH, which is
intended for patients on regular medication with difficulties in
handling their own drugs due to impaired physical or cognitive
function. MDD is used by community-dwelling patients as well as
those who live in nursing homes. In the Region Va ¨stra Go ¨taland,
where this study was performed, eleven per cent of people 65 years
or older use the MDD system as opposed to ordinary prescriptions
(OP). In people 75 years or older the corresponding figure is 19%.
In the MDD system, drugs that should be ingested concomitantly
are delivered in machine-dispensed unit bags. The multi-dose unit
bags are labelled with patient data, drug contents, date, and time
for intake. The bags are usually delivered every fortnight, but
deliveries within a couple of days can be made upon request.
Drugs that cannot be dispensed into the unit bags, for instance
liquids as well as effervescent or chewing tablets, are delivered in
ordinary labelled original packages. These drugs comprise about
half of all drugs prescribed via the MDD system [7]. A specific
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drugs can be viewed. This is not possible with OP. In both systems,
written and electronic prescriptions can be used. Within the MDD
system, drugs for one year utilization can be prescribed at a time.
The same applies to OP, but these have to be filled four times a
year. There are other differences in the prescribing procedure
between the MDD system and OP, and apprehensions have been
raised that these may affect prescribing habits [7,8].
A previous study based on drug register data has reported an
association between MDD and poor quality of drug treatment [9].
However, that study did not take into account diagnoses or
residence. These two covariates should be of importance for drug
treatment, since diagnoses make up the basis for drug treatment,
and MDD is almost mandatory for patients staying in nursing
homes in our region. Therefore, we wanted to make a more
profound investigation with inclusion of these important factors.
Thus, the aim of the present study was to investigate the
association between MDD and quality of drug treatment, with
adjustments for age, sex, burden of disease, and residence.
Materials and Methods
Participants
The study cohort encompassed all inhabitants in Region Va ¨stra
Go ¨taland alive at December 31
st 2007 who met all of the inclusion
criteria: (i) $65 years, (ii) $1 dispensed drug registered in the
Swedish Prescribed Drug Register at any time from the start of the
register (July 1
st 2005) to December 31
st 2007, and (iii) $2 health
care visits for $2 diagnoses within the International Statistical
Classification of Diseases and Related Health Problems (ICD10)
codes for obstructive pulmonary disease (J44–J46), diabetes
mellitus (E10–E14), or cardiovascular disease (I10–I13, I20–I25,
I50) registered in the regional health care consumption database
(VEGA) in 2005–2007. The latter restriction of the study
population was made to make the comparison groups more alike
regarding burden of disease.
The study complies with the Declaration of Helsinki. Ethics
approval was obtained from the Regional Ethical Review Board in
Gothenburg (Dnr 358-08). Informed consent was not applicable
since data were obtained and analysed anonymously. According to
Swedish regulations ethics approval must precede extraction of
register data.
Description of procedures
The study cohort was extracted by linkage of individual data
from the Swedish Prescribed Drug Register with data from the
VEGA database by the unique personal identity number. The
Swedish Prescribed Drug Register contains data on all prescribed
drugs that are dispensed to a specific individual at Swedish
pharmacies. The VEGA database contains consumption of health
care for all inhabitants of Region Va ¨stra Go ¨taland, including in-
hospital as well as primary care diagnoses.
For patients with OP, a medication list at December 31
st, 2007
was estimated from drugs registered in the Swedish Prescribed
Drug Register during the three month period preceding this date
(i.e. October 1
st–December 31
st, 2007) [4]. The rational for this
time frame was the Swedish regulations, where a maximum of
three months’ drug use is reimbursed at one purchase occasion.
The date of the filling of the prescription, the amount of drug
dispensed, and the prescribed dosage was used to estimate the
duration of the dispensed volume of a drug [4], and if this covered
treatment at December 31
st. When prescribed dosage was
incomplete or missing, a daily dose for the actual drug was looked
up from a table derived from the same dataset, with mean daily
doses from prescriptions with known dosage information. For
drugs prescribed as needed we assumed a dosage of 50% of that
for regular drugs. Moreover, we assumed a daily dose of 1 defined
daily dose (DDD) [10] for drugs for external use and for the eye.
In the MDD system, drugs are either dispensed in unit bags with
prescriptions filled every fortnight, or delivered in original
packages. In the Swedish Prescribed Drug Register, prescribed
dosages are currently not included for patients with MDD.
Therefore, we assumed dose-dispensed drugs to be current
medications if filled within 14 days before December 31
st 2007,
whereas the use of drugs delivered in whole packages was assessed
using the method described above for OP with incomplete or
missing dosage information.
For each patient, quality of drug treatment was assessed by five
drug-specific quality indicators, developed by the Swedish
National Board of Health and Welfare: Ten or more drugs, Long-
acting benzodiazepines, Drugs with anticholinergic effects, Three or more
psychotropics, and Drug combinations that should be avoided. These
indicators are all inverted, that is, presence of such treatment,
regularly or as needed, indicates poor quality of drug treatment.
The quality indicators are described in Table 1.
Patient diagnoses were extracted from the VEGA database. As
an estimate of burden of disease, the number of different diagnoses
(ICD10-code, 3 digits) in hospital and primary care was
summarized for each patient. Furthermore, all patients were
categorized as either with or without a psychiatric diagnosis within
the ICD10-codes covering dementia, organic brain disorders,
psychotic disorders, abuse, affective disorders, anxiety, and sleep
disorders (F00–F03, G30, G31.8A, F06, F09, F1–F4, F51.0, F51.9,
G47.0, G47.9).
Residence (nursing home or community-dwelling) on October
1
st 2007 was extracted from the Swedish Social Service Register.
Statistical analysis
The Student’s t-test and the Chi-square test were used for
comparisons between patients with and without MDD. Logistic
regression was performed to evaluate the association between
MDD and the quality of drug treatment. The results were adjusted
for age, sex, burden of disease, and residence. Since psychiatric
diseases may be associated with both residence and MDD, and
several of the drug-specific quality indicators involve drugs
intended for psychiatric diseases, a sensitivity analysis was
performed with Any psychiatric diagnosis as a dummy variable
included in the model. Collinearity between variables in the model
was investigated with Pearson’s correlation. The statistical analyses
were performed by SPSS 17.0.
Results
A total of 24,146 patients were included (mean age [standard
deviation]: 77 [7.2] years; 51% female); 4,927 (20%) with MDD
and 19,219 (80%) with OP. Characteristics of patients are
presented in Table 2. Compared with patients with OP, patients
with MDD were older and more often female, had more drugs and
diagnoses, and more often lived in nursing homes (all P,0.0001).
The proportion of patients with poor quality in drug treatment
according to the quality indicators varied between 5.9% and 55%
for patients with MDD, and between 2.6% and 19% for patients
with OP (Table 3). Patients with MDD showed poorer quality on
all quality indicators than patients with OP (all P,0.0001).
The unadjusted odds for a patient to have poor quality in drug
treatment according to the five drug-specific quality indicators were
between1.47and7.08timeshigherforpatientswithMDD(Table4).
After adjustments for age, sex, burden of disease, and residence, the
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quality indicators on number of concomitant drugs. For all quality
indicators, the odds for poor quality in drug treatment were greater
for MDD than for the other variables included in the model, and in
three out of five quality indicators, the confidence intervals between
MDD and the other variables did not overlap.
When the results were also adjusted for Any psychiatric diagnosis,
the odds ratio (95% confidence interval) for poor quality in drug
treatment was; use of: Ten or more drugs, 3.85 (3.54–4.18); Long-acting
benzodiazepines, 1.39 (1.17–1.65); Drugs with anticholinergic effects, 2.15
(1.89–2.44); Three or more psychotropics, 4.01 (3.48–4.64); and Drug
combinations that should be avoided (D interactions), 1.37 (1.19–1.58).
Correlation coefficients between MDD and the other variables
in the model were 0.32 (age), 0.07 (sex), 0.26 (number of
diagnoses), 0.46 (residence), and 0.24 (any psychiatric diagnosis).
Discussion
Principal findings
Our results indicate that MDD is negatively associated with
quality of drug treatment. Up to five times as many patients with
MDD had poor quality of drug treatment according to drug-
specific quality indicators. Interestingly, this finding can neither be
explained by their being more ill nor their need to stay in a nursing
Table 1. Description of drug-specific quality indicators used in the present study.
Indicator Included drugs ATC-code
1
Ten or more drugs all drugs
Long-acting benzodiazepines diazepam N05BA01
nitrazepam N05CD02
flunitrazepam N05CD03
Drugs with anticholinergic effects (anticholinergic) drugs for functional gastrointestinal disorders A03AB, A03BA, A03BB
(anticholinergic) antiemetics A04AD
antiarrythmics class Ia C01BA
urinary antispasmodics G04BD
opioids in combination with antispasmodics N02AG
anticholinergic (anti-Parkinson drugs) N04A
low potency antipsychotics N05AA, N05AB04, N05AF03
hydroxyzine N05BB01
non-selective monoamine reuptake inhibitors (antidepressants) N06AA
antihistamins R05CA10, R06AA02, R06AB, R06AD, R06AX02
Three or more psychotropics antipsychotics N05A
anxiolytics N05B
hypnotics and sedatives N05C
antidepressants N06A
Drug combinations that should be avoided drugs with D-interactions, as defined in the Pharmaceutical
Specialities in Sweden (FASS) [17]
1ATC-code, Anatomical Therapeutical Chemical classification code [10].
doi:10.1371/journal.pone.0026574.t001
Table 2. Characteristics of patients.
MDD OP P-value
n=4,927 n=19,219
Age, years, mean 6 SD 81.267.2 75.566.7 ,0.0001
Female sex, n (%) 2,860 (58.0) 9,411 (49.0) ,0.0001
Number of drugs at December 31
st 2007, mean 6 SD 10.363.9 6.663.6 ,0.0001
Diagnoses, mean 6 SD Total 17.267.6 12.766.7 ,0.0001
Obstructive pulmonary disease 1,732 (35.2) 6,560 (34.1) 0.18
Diabetes mellitus 3,844 (78.0) 14,634 (76.1) 0.0056
Cardiovascular disease 4,875 (98.9) 18,992 (98.8) 0.46
Psychiatric disease 1,623 (32.9) 1,654 (8.6) ,0.0001
Living in nursing homes, n (%) 1,362 (27.6) 113 (0.6) ,0.0001
MDD, multi-dose drug dispensing; OP, ordinary prescriptions; SD, standard deviation.
doi:10.1371/journal.pone.0026574.t002
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were included in the model. Indeed, the odds ratios for poor
quality of drug treatment for MDD were high as compared with
other patient characteristics. Thus, the MDD system seems to be a
prominent determinant for poor quality of drug treatment. This
finding is interesting, since it indicates that a technology (MDD)
which aims to solve a problem (to facilitate and increase safety in
drug handling for the patient and the health care staff) may
introduce new problems (poorer quality in drug treatment), as
previously discussed [11].
The greatest differences between patients with and without
MDD were found for quality indicators concerning number of
drugs, Ten or more drugs and Three or more psychotropics. These results
could not be explained by a greater burden of disease for patients
with MDD. The results confirm previous assumptions that the
MDD system increases the number of drugs [8], and thus
adjustments for number of drugs, as made in a previous study [9],
may diminish the estimates of the effects of MDD on drug
treatment. Even after adjustment for psychiatric disease, four times
as many patients with MDD had poor quality according to the
quality indicator Three or more psychotropics. One may speculate that
the different prescribing procedures involved in MDD and OP
may affect the quality of prescribing. In the MDD system, all
prescriptions can easily be renewed at the same time, which could
lead to less frequent withdrawals of drugs. In OP, on the other
hand, all prescriptions need to be renewed one at a time. To the
best of our knowledge, no scientific literature is available on the
effects of different prescribing procedures on inclination to make
changes in drug treatment, that is, additions, withdrawals, or
dosage adjustments, over time.
When a patient is treated with numerous drugs, the risk of Drug
combinations that should be avoided would be expected to increase [12].
In the present study, the risk for potentially serious drug-drug
interactions was increased in patients with MDD but to a lower
degree than could be expected from their use of many drugs. One
explanation for this may be that drug-drug interaction warnings
based on the complete medication list of the patient are given in
the MDD prescribing procedure. When prescribing to patients
with OP, drug-drug interaction warnings only occur for drugs
prescribed concomitantly, that is, the complete medication list is
unavailable. Interestingly, previous results concerning MDD
patients and Drug combinations that should be avoided are somewhat
contradictory; the proportion of patients with such combinations
was greater for patients with MDD than for patients with OP
(8.8% vs. 3.7%), but after adjustments for number of dispensed
drugs, the odds including confidence interval was ,1.0 [9].
Limitations
The present study has several limitations. First, the cross-
sectional study design does not allow conclusions concerning
causality between MDD and poor quality in drug treatment. Thus,
we cannot rule out if MDD leads to low quality of drug treatment,
or if low quality of drug treatment leads to MDD. Further
longitudinal research is needed to clarify causality. Moreover,
patients with and without MDD are obviously not alike. Other
factors not included in the multivariate model may be of
Table 3. Number of patients with poor quality in prescribing according to drug-specific quality indicators.
MDD OP P-value
n=4,927 n=19,219
Ten or more drugs, n (%) 2,717 (55.1) 3,671 (19.1) ,0.0001
Long-acting benzodiazepines, n (%) 292 (5.9) 619 (3.2) ,0.0001
Drugs with anticholinergic effects, n (%) 630 (12.8) 1,035 (5.4) ,0.0001
Three or more psychotropics, n (%) 792 (16.1) 506 (2.6) ,0.0001
Drug combinations that should be avoided (D-interactions), n (%) 401 (8.1) 1,094 (5.7) ,0.0001
MDD, multi-dose drug dispensing; OP, ordinary prescriptions.
doi:10.1371/journal.pone.0026574.t003















1, OR (95% CI) 5.21 (4.87–5.57) 1.89 (1.64–2.18) 2.58 (2.32–2.86) 7.08 (6.30–7.96) 1.47 (1.30–1.65)
Multi-dose drug dispensing
1, AOR (95% CI) 3.88 (3.58–4.21) 1.61 (1.36–1.91) 2.32 (2.05–2.63) 5.48 (4.76–6.30) 1.36 (1.18–1.57)
Age
2, AOR (95% CI) 0.99 (0.98–0.99) 0.99 (0.98–1.00) 0.97 (0.96–0.98) 0.96 (0.95–0.97) 0.99 (0.98–0.99)
Female sex
3, AOR (95% CI) 1.27 (1.20–1.36) 1.48 (1.29–1.70) 1.33 (1.20–1.48) 1.42 (1.26–1.60) 1.14 (1.02–1.27)
Number of diagnoses
2, AOR (95% CI) 1.09 (1.09–1.10) 1.05 (1.04–1.05) 1.04 (1.03–1.05) 1.05 (1.04–1.06) 1.04 (1.03–1.04)
Nursing home
4, AOR (95% CI) 1.35 (1.19–1.53) 0.83 (0.63–1.09) 1.24 (1.03–1.49) 2.20 (1.87–2.60) 0.89 (0.71–1.12)
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make the study more efficient by restricting the study population,
that is, to only include older people with established obstructive
pulmonary disease, diabetes mellitus, and/or cardiovascular
disease. Thus, the study population is a subset of all people $65
years in the Region Va ¨stra Go ¨taland (24,146 out of 265,819
[9.1%] at December 31
st 2007 [13]). Furthermore, we have made
an additional attempt to control for confounders by including
important covariates in the model, such as burden of disease,
psychiatric disease, and residence.
Second, our analysis is based on register data only, and the
estimated medication list may not reflect the true drug use, that is,
drug use may be both over- and underestimated. Moreover, drugs
are dispensed more frequently for patients with than without
MDD. This may make the estimated medication list of a patient
with MDD more accurate than that of a patient with OP. It
cannot be ruled out that the differing registration frequency may
have affected the results of the present study. However, the
principle of estimating actual drug use based on prescriptions filled
during a three months period has been employed in several
previous studies [14,15,16], and indeed, the present method used
for estimation of a medication list is the one used by the National
Board of Health and Welfare for calculating quality indicators [6].
Third, the drug-specific quality indicators employed in the
present study do not provide all aspects of quality of drug
treatment. Indeed, all the quality indicators in our study reflect
inappropriate drug use. The study does not examine undertreat-
ment with drugs, for example, when treatment with bisphospho-
nates is lacking in patients at high risk of fractures.
Fourth, data from the Swedish Prescribed Drug Register do not
include drugs for in-hospital use or drugs sold over-the-counter.
Moreover, the register is incomplete as regards drugs used in
nursing homes; occasionally in such residencies, medications from
drug storerooms are dispensed without being registered in the
Swedish Prescribed Drug Register, e.g. antibiotics for short-time
use and temporary analgesics.
Future research
Summarized, patients with MDD have poorer quality in their
drug treatment than patients with OP, and this cannot be
explained by differences in age, sex, burden of disease, or
residence. These findings should have implications for countries
which already have or plan to introduce dose dispensing systems.
Further research is needed to evaluate causative factors and if the
findings also apply to other dose dispensing systems.
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